Biosimilar Onslaught and Roche’s Direct Counterattack

Roche Holding AG (RHHBY) is facing a serious revenue hit due to patent expirations of its existing blockbuster products. From 2025 to 2030, eight oncology and autoimmune therapeutics will encounter biosimilar competition, potentially eroding approximately CHF 6.7 billion (about $7.4 billion) in sales. In response, Roche’s management is rapidly diversifying its R&D portfolio to secure new growth engines. This demonstrates a strong commitment to shift the business model from a cancer‑centric structure to one focused on obesity and next‑generation targeted therapies.

Next‑Generation Estrogen Receptor Degrader Giredestrant’s Potential

The breast‑cancer candidate that Roche is most optimistic about, Giredestrant, is an oral selective estrogen receptor degrader (SERD) targeting hormone‑receptor‑positive, HER2‑negative (ER+/HER2‑) patients. Because its target population is considerably broader than that of the former blockbuster Herceptin, Roche expects the drug could generate more than $3 billion in annual revenue. The FDA is currently reviewing the application under a Priority Review Voucher, with decisions on adjuvant early‑stage breast cancer expected by November 30, 2026, and on metastatic indication by December 18, 2026. Although some concerns were raised in recent first‑line clinical trials, approval would make Giredestrant the first widely available oral SERD, substantially improving convenience and representing a potential game‑changer.

Diversifying the Obesity Therapeutics Market with an Amylin Analog

The obesity market is currently dominated by Eli Lilly and Novo Nordisk, but Roche has devised a strategy to enter the space with a differentiated mechanism of action. Roche licensed Petrelintide from Zealand Pharma; Petrelintide is a long‑acting amylin analog that, unlike existing GLP‑1 receptor agonists, is associated with fewer side effects and superior tolerability. Roche anticipates high adherence for both injectable and oral formulations of Petrelintide and projects a revenue potential exceeding $3 billion annually. Given the rapid rise in global obesity prevalence, the molecule could become a valuable alternative for patients who are sensitive to side‑effects.

Completion of a Multi‑Modal Obesity Pipeline Through the Carmot Therapeutics Acquisition

Beyond Zealand Pharma’s standalone pipeline, Roche is targeting the obesity market with a multi‑agonist portfolio secured through the 2023 acquisition of Carmot Therapeutics. The lead candidate, CT‑388, is a dual GLP‑1/GIP co‑agonist; oral small‑molecule CT‑996 and CT‑868 for type‑1 diabetes are also progressing smoothly in clinical development. Roche predicts that the assets obtained from Carmot could generate an additional $3 billion in annual sales through combination regimens and other indications. This milestone could usher in an era of precision obesity therapy tailored to individual metabolic profiles, extending beyond simple weight loss.